News Releases
Business Wire|November 5, 2024
Be Biopharma Announces Upcoming Presentation at the 66th American Society of Hematology (ASH) Annual Meeting
Business Wire|October 22, 2024
Be Bio Announces $82 Million Financing and Transition to Clinical Stage Company
Business Wire|September 30, 2024
Be Biopharma Announces Preclinical Data for Novel Engineered B Cell Medicine for the Potential Treatment of Hypophosphatasia
June 4, 2024
FDA Grants Orphan Drug Designation for BE-101, a Novel Engineered B Cell Medicine, for the Treatment of Hemophilia B
May 28, 2024
Be Biopharma Announces FDA Clearance of IND Application for BE-101 in Hemophilia B
May 21, 2024
Be Biopharma Expands Scientific Advisory Board with the Appointment of Cell and Gene Therapy Leader Dr. Paula Cannon
May 10, 2024
Be Biopharma Announces New Preclinical Data for Novel B Cell Medicine for the Potential Treatment of Hypophosphatasia
April 23, 2024
Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
February 1, 2024
Be Biopharma to Present at the 20th Annual WORLDSymposium™ 2024
January 25, 2024
Be Biopharma to Present at Keystone Symposia on Emerging Cellular Therapies
January 4, 2024
Be Biopharma Expands Leadership Team as Company Transitions to Clinical Stage Organization
December 28, 2023
Be Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 10, 2023
Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-101, Produces Active and Sustained Levels of Factor IX for the Treatment of Hemophilia B
November 22, 2023
Be Biopharma to Present at the 35th Annual Piper Sandler Healthcare Conference
November 2, 2023
Be Biopharma to Present New Preclinical Study Demonstrating Its Precision-Engineered B Cell Medicine Produces Active and Sustained Levels of Factor IX
October 31, 2023
Be Biopharma Presents Preclinical Data Demonstrating Ex-Vivo Engineered B Cell Medicines Produce Highly Active and Sustained Levels of Antitumor Biologics
October 25, 2023
Be Biopharma Presents Data from Preclinical Studies Showing Engineered B Cells Produce Highly Active Therapeutic Proteins and Demonstrate Durable Engraftment Without Pre-Conditioning
October 11, 2023
Be Biopharma to Present at 2023 Cell & Gene Meeting on the Mesa
May 25, 2023
Be Biopharma to Present at the Jefferies Healthcare Conference
May 19, 2023
Be Biopharma Study Shows First Demonstration of Rapid Engraftment of B Cells without Preconditioning in Non-Human Primates with Intact Immune Systems
May 18, 2023
Be Biopharma Announces Oral Presentation on Precise Genome Engineering of Human B Cells to Express Diverse Therapeutic Proteins at American Society of Gene & Cell Therapy 26th Annual Meeting
May 2, 2023
Be Biopharma Announces First Scientific Disclosures and New Preclinical Data Supporting the Advancement of B Cell Medicines at the American Society of Gene & Cell Therapy 26th Annual Meeting
December 8, 2022
Be Biopharma Appoints John Mayfield, Ph.D., as Chief Business Officer
May 19, 2022
Be Bio and Resilience Announce Strategic Collaboration to Manufacture Engineered B Cells, a New Class of Cellular Medicines
April 14, 2022
Be Bio Closes $130 Million Financing to Pioneer Engineered B Cells, a New Class of Cellular Medicines
December 16, 2021
Be Bio Announces Appointment of Jay Backstrom, M.D., M.P.H., to Board of Directors
August 11, 2021
Be Bio Appoints Leading Cell & Gene Therapy Executives, Krishnan Viswanadhan as President & Chief Operating Officer, and Brad Hartman as Chief People Officer
March 16, 2021
Be Bio Announces Appointment of Cell and Gene Therapy Veterans Joanne Smith-Farrell, Ph.D., as Chief Executive Officer and Rick Morgan, Ph.D., as Chief Scientific Officer
October 22, 2020
Be Biopharma Launches with $52 Million Series A Financing to Advance B Cells as Medicines
Endpoints News|May 28, 2024
Second engineered B cell therapy enters the clinic, promising to do in hemophilia B what gene therapies can’t
The Long Run with Luke Timmerman|February 14, 2023
Engineered B Cell Therapies for Cancer & Rare Diseases: Joanne Smith-Farrell on The Long Run
Pharmaceutical Technology|May 20, 2022
Be Bio, Resilience to manufacture engineered B cells for rare diseases
Endpoints News|May 19, 2022
Resilience inks manufacturing pact with ARCH-backed cell therapy startup as it preps for the long haul
Biocentury|April 14, 2022
B round for Be Bio’s B cells: Arch leads $130M funding for cell engineering start-up
Boston Business Journal|April 14, 2022
Arch leads $130M round for cell therapy startup targeting cancer, rare disease
Endpoints News|April 14, 2022
ARCH leads $130M infusion into Be Bio’s long pursuit of B cell therapies for rare disease, cancer
Fierce Biotech|April 14, 2022
Be Bio uses Arch Venture-led $130M financing round to harness ‘power of the B cell’
Endpoints News|October 22, 2020
Can B cells break the boundaries of cell therapy? Longwood startup has $52M to prove a new engineering tech
FierceBiotech|October 22, 2020
Be Biopharma debuts with $52M to advance engineered B-cell therapies
Boston Business Journal|October 22, 2020
